DLA Piper appoints Josh Kaufman as co-chair of the capital markets group

DLA Piper has officially welcomed Joshua A. Kaufman to co-chair its capital markets and public company advisory practice.

Kaufman will operate from the firm's offices in New York and Miami. His expertise lies in advising high-growth businesses on financing pathways, strategic development, and transformational transactions. His practice strongly emphasizes cross-border matters, with a significant track record of advising leading companies across the United Kingdom, the Nordics, Continental Europe, and Israel.

Kaufman has represented US and foreign private issuers and underwriters in his career, focusing primarily on the life sciences and technology sectors. His work encompasses a broad range of public offerings and private placements, contributing to over 200 financing transactions collectively surpassing US$100 billion in value. Kaufan has frequently represented clients before the Securities and Exchange Commission and his advice on corporate governance, general corporate, and commercial matters.

His portfolio includes advising underwriting syndicates in the US's first dual listings of companies from Denmark and Sweden, assisting a New York biotech company with its US$40 million IPO and several follow-on offerings, and supporting a national restaurant chain through its US$140 million primary and US$75 million at-the-market offerings. Kaufman's experience also extended to managing the transition of UK-listed biotech to Nasdaq and facilitating four IPOs out of Israel, totalling US$1.2 billion.

“Josh’s strong cross-border practice and vast knowledge of the increasingly complex transactional landscape, especially in rapidly growing sectors like life sciences and technology, will further invigorate the positive momentum of our capital market practice,” said Era Anagnosti, co-chair of DLA Piper’s capital markets and public company advisory practice. “His experience and leadership will be strong assets for our team and our clients, and we’re eager to have him on board.”

Andy Gilbert, chair of the US corporate practice at DLA Piper, highlighted the firm's ongoing expansion of its capital markets, M&A, and venture capital capabilities within the life sciences and technology sectors. Gilbert expressed confidence that Kaufman will significantly add to their robust capital markets team, particularly in these key areas.